Susan Keizer, in Oacoma, SD - Speech-Language Pathologist

Susan Keizer, is a Speech-language Pathologist based in Oacoma, South Dakota. Susan Keizer is licensed to practice in South Dakota (license number 265-SLP) and her current practice location is 105 N. Seaman, #18, Oacoma, South Dakota. She can be reached at her office (for appointments etc.) via phone at (605) 354-0011.

NPI number for Susan Keizer is 1811344773 and her current mailing address is Po Box 213, Oacoma, South Dakota. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1811344773.

Contact Information

	Susan Keizer,
	105 N. Seaman, #18, Oacoma, SD 57365
	(605) 354-0011
	Not Available

Healthcare Provider's Profile

Full Name	Susan Keizer
Gender	Female
Speciality	Speech-language Pathologist
Location	105 N. Seaman, Oacoma, South Dakota
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1811344773
Provider Enumeration Date: 05/20/2016
Last Update Date: 05/23/2016

Medical Identifiers

Medical identifiers for Susan Keizer such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1811344773	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
235Z00000X	Speech-language Pathologist	265-SLP (South Dakota)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Susan Keizer is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Susan Keizer, Po Box 213, Oacoma, SD 57365-0213 Ph: () -	Susan Keizer, 105 N. Seaman, #18, Oacoma, SD 57365 Ph: (605) 354-0011

News Archive

Merck researchers to participate in two new collaborative efforts to study HIV latency

Merck, known as MSD outside the United States and Canada, today announced that company researchers will participate in two new collaborative efforts led by the prominent academic institutions of the University of North Carolina (UNC) Chapel Hill and the University of California San Francisco (UCSF) to develop new approaches towards eradicating HIV, the virus that causes AIDS.

Researchers identify best time for stem cell collection for Parkinson's therapy

Researchers have identified a stage during dopamine neuron differentiation that may be an ideal time to collect human embryonic stem cells for transplantation to treat Parkinson's disease, according to data presented at Neuroscience 2008, the 38th annual meeting of the Society for Neuroscience.

New research examines behaviour of young people lured into internet gambling

New research from the University of Adelaide has studied the behaviour of young people lured into internet gambling through so-called 'free-play' or 'practice' modes.

Researchers offer new perspective on pyrethroid insecticides

In an invited Commentary just published in JAMA Internal Medicine, Columbia Mailman School of Public Health professors Drs. Steven Stellman and Jeanne Mager Stellman offer their perspective on results from a recent study on Pyrethroid, among the most widely used insecticides in the world for public health control of vector-borne illnesses, including West Nile virus.

New nanomedicine allows glaucoma patients to do away with daily eye drops

Scientists from Nanyang Technological University (NTU) and the Singapore Eye Research Institute (SERI) have jointly developed a new nanomedicine that will allow glaucoma patients to do away with daily eye drops.

Susan Keizer, - Speech-Language Pathologist in Oacoma, SD